The New Drug Application (NDA) for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for patients with HIV-1 infection has been submitted to the Food and Drug Administration (FDA).
Activists have been urging Gilead to make the generic drug more widely available.
Truvada is approved in combination with safer sex practices for HIV-1 PrEP to reduce the risk of sexually acquired HIV-1.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Zero rate of HIV transmission seen through condomless sex when viral load is suppressed
Facial involves injecting nutrient-rich plasma into the face using a microneedling pen.
Monotherapy with UB-421 antibody, which blocks the HIV virus-binding site on human CD4+ T-cells, maintains viral suppression for up to 16 weeks in HIV-infected persons undergoing analytic treatment interruption.
Doravirine resistance is uncommon in people with HIV who have been treated with non-nucleoside reverse transcriptase inhibitors.
Significant levels of cytomegalovirus DNA are common in older African children with perinatally acquired HIV infection.
Dovato indicated for use in patients with no history of antiretroviral treatment.
Among US veterans with HIV infection, depressive symptoms are associated with a significantly increased risk for mortality.
Investigators sought to categorize hepatitis C virus infections in HIV-positive MSM as either domestically or internationally acquired and evaluate how this classification changed over time.
People living with HIV and declining cognition exhibit hyperinsulinemia as well as abnormal cholesterol and lipid metabolism.
Compared with patients without HIV, the poorer cognitive performances of PLWHIV were partly mediated by a higher prevalence of depressive symptoms.
Almost 80% of new transmissions from people not aware or aware but not receiving regular care.
Sustained virologic response to the HCV in patients with HCV and HIV coinfection is associated with a lowered risk of diabetes and mortality.
HIV during the perinatal period in the US have declined over recent decades, but its prevalence rates in female adults and adolescents continues to rise.
ViiV Healthcare announced positive 48-week data from the phase 3 ATLAS (N=616) and FLAIR (N=566) studies evaluating a long-acting injectable formulation of cabotegravir + rilpivirine in patients with HIV-1 infection.
Interventions to reduce some traditional risk factors can improve the proportion of non-AIDS-related comorbidities.
There is a significant need for identifying people with HIV infection who are unaware of their infection status and linking them to HIV care.